Clinical Trial Update: Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine and nivolumab as subsequent-line therapy for metastatic small cell lung cancer; study status terminated with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• nivolumab (nivolumab)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Status: TERMINATED | Results posted: 2021-11-12